British Journal of Rheumatology 1991 ;30:451-454
CLINICAL PRACTICE
SHOULD DISEASE-MODIFYING AGENTS BE USED IN MILD RHEUMATOID ARTHRITIS? BY M. J. DAVIS, P. T. DAWES, P. D. FOWLER, S. CLARKE, J. FISHER AND M. F. SHADFORTH Staffordshire Rheumatology Centre, Stoke-on-Trent
SUMMARY A 12-month double-blind controlled study comparing hydroxychloroquine 400 mg daily with placebo in 104 patients with mild RA was conducted to see whether patients with mild rheumatoid arthritis (RA) benefit from treatment with diseasemodifying agents. Mild RA was denned as synovitis limited to the hands and feet, an ESR
CLINICAL PRACTICE
SHOULD DISEASE-MODIFYING AGENTS BE USED IN MILD RHEUMATOID ARTHRITIS? BY M. J. DAVIS, P. T. DAWES, P. D. FOWLER, S. CLARKE, J. FISHER AND M. F. SHADFORTH Staffordshire Rheumatology Centre, Stoke-on-Trent
SUMMARY A 12-month double-blind controlled study comparing hydroxychloroquine 400 mg daily with placebo in 104 patients with mild RA was conducted to see whether patients with mild rheumatoid arthritis (RA) benefit from treatment with diseasemodifying agents. Mild RA was denned as synovitis limited to the hands and feet, an ESR
